| Literature DB >> 25414663 |
Abstract
Synapse efficacy heavily relies on the number of neurotransmitter receptors available at a given time. In addition to the equilibrium between the biosynthetic production, exocytic delivery and recycling of receptors on the one hand, and the endocytic internalization on the other, lateral diffusion and clustering of receptors at the cell membrane play key roles in determining the amount of active receptors at the synapse. Mobile receptors traffic between reservoir compartments and the synapse by thermally driven Brownian motion, and become immobilized at the peri-synaptic region or the synapse by: (a) clustering mediated by homotropic inter-molecular receptor-receptor associations; (b) heterotropic associations with non-receptor scaffolding proteins or the subjacent cytoskeletal meshwork, leading to diffusional "trapping," and (c) protein-lipid interactions, particularly with the neutral lipid cholesterol. This review assesses the contribution of some of these mechanisms to the supramolecular organization and dynamics of the paradigm neurotransmitter receptor of muscle and neuronal cells -the nicotinic acetylcholine receptor (nAChR). Currently available information stemming from various complementary biophysical techniques commonly used to interrogate the dynamics of cell-surface components is critically discussed. The translational mobility of nAChRs at the cell surface differs between muscle and neuronal receptors in terms of diffusion coefficients and residence intervals at the synapse, which cover an ample range of time regimes. A peculiar feature of brain α7 nAChR is its ability to spend much of its time confined peri-synaptically, vicinal to glutamatergic (excitatory) and GABAergic (inhibitory) synapses. An important function of the α7 nAChR may thus be visiting the territories of other neurotransmitter receptors, differentially regulating the dynamic equilibrium between excitation and inhibition, depending on its residence time in each domain.Entities:
Keywords: 2D-diffusion; acetylcholine receptor; cholesterol; lateral mobility; membrane domains; receptor clustering
Year: 2014 PMID: 25414663 PMCID: PMC4220116 DOI: 10.3389/fnsyn.2014.00025
Source DB: PubMed Journal: Front Synaptic Neurosci ISSN: 1663-3563
Diffusion coefficients of muscle-type nAChR measured by the FRAP technique.
| Condition | Reference | ||
|---|---|---|---|
| Developing myotubes, synaptic | <10-4 | ||
| Extrasynaptic | 0.5 × 10-2 | ||
| Adult rat muscle fibers culture | 0.25 × 10-2 | ||
| Control cells | 0.56 ± 0.09 | 0.46 ± 0.09 × 10-2 | |
| 10 mM CDx-treated | *0.19 ± 0.12 | *0.27 ± 0.08 × 10-2 | |
| 20 mM Latrunculin A | 0.44 ± 0.04 | 0.67 ± 0.18 × 10-2 | |
| 10 mM CDx + 20 mM Latrunculin A | 0.28 ± 0.10 | 0.49 ± 0.21 × 10-2 | |
| 3.5 mM CDx-cholesterol (6:1) | 0.62 ± 0.08 | 0.63 ± 0.26 × 10-2 | |
| 10 mM CDx-cholesterol (6:1) | 0.54 ± 0.10 | *1.17 ± 0.44 × 10-2 |
Mobility parameters of nAChR particles in samples labeled with Alexaα-BTX or with a primary anti-nAChR monoclonal antibody (mAb210) followed by staining with Alexa-labeled secondary antibody, with or without treatment with 15 mM methyl-β-cyclodextrin (CDx).
| Experiment | Average lifetime (s) | Average displacement (μm) | Average velocity (μm/ms) | Total no. of particles (in all frames) | Total no. compound tracks analyzed |
|---|---|---|---|---|---|
| BTX control | 4.06 ± 0.78 | 4.05 ± 0.27 | 0.0011 ± 0.0002 | 4535 | 121 |
| BTX CDx (10 min) | 4.11 ± 0.61 | 4.54 ± 0.36 | 0.0010 ± 0.0002 | 3759 | 101 |
| BTX CDx (15 min) | 5.30 ± 0.80 | 4.42 ± 0.06 | 0.0009 ± 0.0001 | 4574 | 128 |
| mAb control | 10.47 ± 0.31a | 4.36 ± 0.02a | 0.0004 ± 0.0001 | 7772 | 69 |
| mAb CDx (10 min) | 11.06 ± 3.11b | 2.13 ± 0.25b* | 0.0002 ± 0.0001 | 5987 | 53 |
| mAb CDx (20 min) | 13.41 ± 1.44c | 4.76 ± 0.72c | 0.0005 ± 0.0001 | 3755 | 41 |
| mAb CDx (40 min) | 19.96 ± 0.68d* | 5.70 ± 1.18d | 0.0003 ± 0.0001 | 4409 | 29 |
Mean square displacement (MSD) of nAChR particles in samples labeled with Alexaα-BTX or with anti-nAChR monoclonal antibody (mAb210) followed by staining with Alexa-labeled secondary antibody, with or without treatment with 15 mM methyl-β-cyclodextrin (CDx).
| Experimental condition | Total no. of particles (in all frames) | No. of frames analyzed to determine trajectory | Total no. compound tracks analyzed | Mean square displacement (μm2) |
|---|---|---|---|---|
| BTX Control | 42,625 | 15 | 1702 | 0.0589 ± 0.0016 |
| 30 | 1530 | 0.0936 ± 0.0028 | ||
| 60 | 1462 | 0.1550 ± 0.0056 | ||
| BTX CDx | 18,728 | 15 | 1572 | 0.0874 ± 0.0079 |
| 30 | 1120 | 0.1597 ± 0.0177 | ||
| 60 | 862 | 0.2255 ± 0.0206 | ||
| mAb Control | 15,297 | 15 | 1476 | 0.0436 ± 0.0032 |
| 30 | 1126 | 0.0671 ± 0.0049 | ||
| 60 | 861 | 0.0974 ± 0.0077 | ||
| mAb CDx | 104,227 | 15 | 956 | 0.0242 ± 0.0019 |
| 30 | 620 | 0.0388 ± 0.0031 | ||
| 60 | 388 | 0.0668 ± 0.0105 | ||
Distribution of free and clustered nAChR particles in CHO/K1-A5 cells (see also Figure ).
| Experiment | Total number of particles | Particles in clusters | |
|---|---|---|---|
| BTX control | 938.1 ± 214a | 895.8 ± 209 (95.1%)a | |
| BTX CDx (10 min) | 514.4 ± 192b* | 470.6 ± 182 (91.4%)b* | |
| BTX CDx (15 min) | 931.2 ± 262c | 886.6 ± 269 (95.2%)c | |
| mAb control | 736.7 ± 474d* | 680.7 ± 455 (92.3%)d* | |
| mAb CDx (10 min) | 8930.8 ± 3200e* | 8859.9 ± 3183 (99.2%)e* | |
| mAb CDx (20 min) | 5521.3 ± 2776f | 5487.3 ± 2761 (99.34%)f | |
| mAb CDx (40 min) | 1151.1 ± 995g | 1134.3 ± 990 (98.54%)g | |